Citations 21
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Richardson, Paul G. , Vij, Ravi , Chen, Christine , Jakubowiak, Andrzej , Song, Kevin , Belch, Andrew , Shustik, Chaim, Lentzsch, Suzanne , Lacy, Martha Q. , Matous, Jeffrey, Vesole, David H. , Chen, Min , Zaki, Mohamed H. , Jacques, Christian , Yu, Zhinuan, Richardson, Paul Gerard Guy , Siegel, David S. , Hofmeister, Craig C. , Baz, Rachid , Jagannath, Sundar , Lonial, Sagar , Bahlis, Nizar Jacques , Raje, Noopur , Mıkhael, Joseph , Anderson, Kenneth C.
Blood | January 13, 2014 | Volume: 123 | Issue: 12 | Pages: 1826-1832
Key Points Pomalidomide plus low-dose dexamethasone significantly improved PFS vs pomalidomide alone in relapsed and refractory multiple myeloma. Pomalidomide plus low-dose dexamethasone is an important new treatment option for RRMM patients who have received multiple prior therapies.